Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cefixime. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 8/20 | 1.00 |
| ▸ | APEX1 | P27695 | 3/20 | 1.00 |
| ▸ | APAF1 | O14727 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | PLCG1 | P19174 | 1/20 | 1.00 |
| ▸ | ABCC2 | Q92887 | 1/20 | 1.00 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 1.00 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.98 |
| ▸ | MMP2 | P08253 | 1/20 | 0.98 |
| ▸ | MAPT | P10636 | 4/20 | 0.79 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.79 |
| ▸ | CNR1 | P21554 | 1/20 | 0.79 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.79 |
| ▸ | NR1I2 | O75469 | 5/20 | 0.64 |
| ▸ | HTR2C | P28335 | 1/20 | 0.64 |
| ▸ | PPARG | P37231 | 2/20 | 0.61 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.61 |
| ▸ | SLC22A8 | Q8TCC7 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cefixime SCHEMBL3553111 | 1.00 | TDP1 (1.00) | TDP1APEX1APAF1LMNAL3MBTL1 | |
| Cefixime SCHEMBL4812946 | 1.00 | TDP1 (1.00) | TDP1APEX1APAF1LMNAL3MBTL1 | |
| Cefixime SCHEMBL17131963 | 1.00 | TDP1 (1.00) | TDP1APEX1APAF1LMNAL3MBTL1 | |
| Cefixime SCHEMBL16072825 | 1.00 | TDP1 (1.00) | TDP1APEX1APAF1LMNAL3MBTL1 | |
| Cefixime SCHEMBL9483204 | 1.00 | TDP1 (1.00) | TDP1APEX1APAF1LMNAL3MBTL1 | |
| Cefixime SCHEMBL12374914 | 1.00 | TDP1 (1.00) | TDP1APEX1APAF1LMNAL3MBTL1 | |
| Cefixime SCHEMBL4812929 | 1.00 | TDP1 (1.00) | TDP1APEX1APAF1LMNAL3MBTL1 | |
| Cefixime SCHEMBL9483213 | 1.00 | TDP1 (1.00) | TDP1APEX1APAF1LMNAL3MBTL1 | |
| Cefixime SCHEMBL49534 | 1.00 | TDP1 (1.00) | TDP1APEX1APAF1LMNAL3MBTL1 | |
| Cefixime SCHEMBL28541257 | 1.00 | TDP1 (1.00) | TDP1APEX1APAF1LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050032771-A1 | Process for the preparation of cefixime via alkyl-or aryl-sulfonates | ANTIBIOTICOS S.P.A. (IT) | 2005-02-10 | — | — | US | claimed |
| EP-1442044-A1 | A PROCESS FOR THE PREPARATION OF CEFIXIME VIA ALKYL-OR ARYL-SULFONATES | Antibioticos S.p.A. (IT) | 2004-08-04 | — | — | EP | claimed |
| EP-0968214-B1 | PURIFICATION PROCESS | BIOCHEMIE GMBH (AT) | 2004-04-07 | — | — | EP | claimed |
| WO-2003040148-A1 | A PROCESS FOR THE PREPARATION OF CEFIXIME VIA ALKYL-OR ARYL-SULFONATES | ANTIBIOTICOS S.P.A. (IT) | 2003-05-15 | — | — | WO | claimed |
| US-6313289-B1 | MAKING CEFIXIME; 7-AMINO-3-VINYL-3-CEPHEM-4-CARBOXYLIC ACID AND 2-(AMINOTHIAZOL-4-YL)-2-CARBOXYMETHOXYIMINO)ACETIC ACID ESTER ARE REACTED; BY-PRODUCT INHIBITION; SALT FORMATION, AMINATION | BIOCHEMIE GESELLSCHAFT M.B.H. (AT) | 2001-11-06 | — | — | US | claimed |
| EP-0968214-A1 | PURIFICATION PROCESS | BIOCHEMIE GESELLSCHAFT M.B.H. (AT) | 2000-01-05 | — | — | EP | claimed |
| WO-1998031685-A1 | PURIFICATION PROCESS | BIOCHEMIE GESELLSCHAFT MBH (AT) | 1998-07-23 | — | — | WO | claimed |
| EP-0030630-B1 | 7-ACYLAMINO-3-VINYLCEPHALOSPORANIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM; THEIR STARTING COMPOUNDS AND THEIR PREPARATION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1987-04-01 | — | — | EP | claimed |
| US-4409214-A | Including cefixime; antibiotics | FUJISAWA PHARMACEUTICAL, CO., LTD. (JP) | 1983-10-11 | — | — | US | claimed |
| EP-0030630-A2 | 7-Acylamino-3-vinylcephalosporanic acid derivatives, processes for their preparation, pharmaceutical compositions containing them; their starting compounds and their preparation | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-06-24 | — | — | EP | claimed |
| JP-56086187-A | — | — | None | — | — | JP | disclosed |
| JP-1149728-A | — | — | None | — | — | JP | disclosed |
| JP-62277391-A | — | — | None | — | — | JP | disclosed |
| US-7705142-B2 | Process for the preparation of cefixime | HETERO DRUGS LIMITED (IN) | 2010-04-27 | — | — | US | disclosed |
| EP-1863822-B1 | AN IMPROVED PROCESS FOR THE PREPARATION OF CEFIXIME | HETERO DRUGS LTD (IN) | 2009-10-14 | — | — | EP | disclosed |
| EP-0123024-A2 | 7-Acylamino-3-vinylcephalosporanic acid derivatives, processes for their preparation, pharmaceutical compositions containing them; their starting compounds and their preparation | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-10-31 | — | — | EP | disclosed |
| US-4423213-A | ANTIBIOTIC | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-12-27 | — | — | US | disclosed |
| US-4409214-A | Including cefixime; antibiotics | FUJISAWA PHARMACEUTICAL, CO., LTD. (JP) | 1983-10-11 | — | — | US | disclosed |
| JP-S5686187-A | 7-ACYLAMINO-3-VINYLCEPHALOSPORANIC ACID DERIVATIVE AND ITS PREPARATION | FUJISAWA PHARMACEUT CO LTD | 1981-07-13 | — | — | JP | disclosed |
| EP-0030630-A2 | 7-Acylamino-3-vinylcephalosporanic acid derivatives, processes for their preparation, pharmaceutical compositions containing them; their starting compounds and their preparation | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032771-A1 | Process for the preparation of cefixime via alkyl-or aryl-sulfonates | CYP4X1, SULT1E1, SULT2A1 | TDP1 4871/4885APEX1 4232/4885APAF1 3935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.